{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003777","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.257547+00:00","generated_at":"2026-06-01T09:41:13.777353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M","bullets":["Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.","Net loss of $(1,283,801) improved from $(1,702,430) in the prior-year quarter.","Gross profit rose to $2,354,337 from $1,828,122, driven by new product launches.","In February 2024, completed public offering for gross proceeds of ~$10 million.","Growth attributed to expanded sales efforts by subsidiary Nora Pharma Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003777","json":"https://secwatch.observer/filing/0001683168-24-003777.json","markdown":"https://secwatch.observer/filing/0001683168-24-003777.md","text":"https://secwatch.observer/filing/0001683168-24-003777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824003777/0001683168-24-003777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824003777/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:41:13.777353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}